Loading
Sentiment · FY2026 Q2
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $29.21B | +10.4% | $-5.76 | -30.3% | -3.1% | -2.4% | $-682M |
| FY2025 Q1 | $32.11B | +8.4% | $10.30 | +68.6% | 6.3% | 3.9% | $236M |
| FY2025 Q2 | $32.39B | +9.6% | $4.51 | -19.9% | 3.4% | 1.7% | $1.16B |
| FY2025 Q3 | $32.65B | +11.1% | $1.62 | -59.3% | 1.2% | 0.6% | $836M |
| FY2025 Q4 | $32.52B | +11.3% | $-6.61 | -14.8% | -3.2% | -2.4% | $-1.85B |
| FY2026 Q1 | $39.65B | +23.5% | $9.83 | -4.6% | 4.4% | 3.0% | $1.13B |
| FY2026 Q2 | $40.87B | +26.2% | $5.72 | +26.8% | 3.3% | 1.7% | $-558M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Humana delivered a Q1 performing in line to better than expectations across all early indicators, with revenue growing 23% year-over-year as the approximately 1 million new MA members contributed their first full quarter. The 2027 bid strategy prioritized margin trajectory to at least 3% by 2028, and Stars BY28 tracking was on track with BY29 showing strong early starts. Management maintained the at-least-$9 adjusted EPS guidance for 2026 with IBNR reserving up 35% versus 22% membership growth, reflecting prudent conservatism.
Margin | Competitive Dynamics | Cost Pressure | Subscriber Growth | Regulation Policy | Guidance Reliability | Capex Investment | Revenue Growth | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 6 | 5 | 4 | 1 | 6 | 4 | 2 | |
| 2025Q1 | 7 | 2 | 4 | 3 | 4 | 4 | 1 | 3 |
| 2025Q2 | 2 | 5 | 4 | 4 | 5 | 2 | 1 | 3 |
| 2025Q3 | 10 | 7 | 1 | 7 | 3 | |||
| 2025Q4 | 9 | 6 | 4 | 5 | 2 | 2 | 2 | |
| 2026Q1 | 6 | 3 | 8 | 2 | 1 | 1 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Margin | 6 | 7 | 2 | 10 | 9 | 6 |
| Competitive Dynamics | 5 | 2 | 5 | 7 | 6 | 3 |
| Cost Pressure | 4 | 4 | 4 | 1 | 4 | 8 |
| Subscriber Growth | 1 | 3 | 4 | 7 | 5 | 2 |
| Regulation Policy | 6 | 4 | 5 | 3 | 2 | 1 |
| Guidance Reliability | 4 | 4 | 2 | 2 | 1 | |
| Capex Investment | 2 | 1 | 1 | 2 | 1 | |
| Revenue Growth | 3 | 3 | 1 |
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| A.J. Rice | UBS | 7 (14%) |
| Justin Lake | Wolfe Research | 7 (0%) |
| Ben Hendrix | RBC Capital Markets | 7 (14%) |
| Ann Hynes | Mizuho Securities | 7 (0%) |
| Steve Baxter | Wells Fargo | 6 (17%) |
| Andrew Mok | Barclays | 6 (0%) |
| Josh Raskin | Nephron Research | 5 (0%) |
| Erin Wright | Morgan Stanley | 5 (0%) |
| Whit Mayo | Leerink Partners | 5 (0%) |
| Lance Wilkes | Bernstein | 5 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Bank of America | 2 | 7 (14%) |
| Mizuho Securities | 1 | 7 (0%) |
| RBC Capital Markets | 1 | 7 (14%) |
| UBS | 1 |
What HUM and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“some timing-related items related to the Villages Health acquisition that as we continue to integrate, we'll see improvement for the rest of the year.”
Humana is integrating its Villages Health acquisition within CenterWell.
“I would say that Welsh Carson has been an amazing partner to us, and we're proud of what we've built together”
Welsh Carson is Humana's private-equity JV partner in its CenterWell primary-care clinics, with put/call decisions pending.
“we recently completed the acquisition of Max Health. This is a Florida-based primary care organization that will expand CenterWell's reach into new critical markets.”
Humana closed the acquisition of Max Health, a Florida primary-care organization, to expand CenterWell.
| 7 (14%) |
| Wolfe Research | 1 | 7 (0%) |
| Barclays | 1 | 6 (0%) |
| Wells Fargo | 1 | 6 (17%) |
| Goldman Sachs | 1 | 5 (0%) |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
HUM Humana | 7 | +23.5% | |
| CI Cigna | 8 | +4.6% | |
| CNC Centene Corporation | 9 | +7.1% | |
| CVS CVS Health | 9 | +6.2% | |
| ELV Elevance Health | 7 | +2.6% | |
| UNH UnitedHealth Group Incorporated | 7 | +2.0% |